• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does 5-Fluorouracil Effectively Treat Vaginal Intraepithelial Neoplasia and Prevent Recurrence?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • 5-fluorouracil is used off-label to treat Vaginal Intraepithelial Neoplasia (VIN)
  • Fiascone et al. (Obstetrics & Gynecology, 2017) sought to assess the success rate of 5-fluorouracil in the treatment and prevention of high-grade VIN recurrence

METHODS:

  • Retrospective case series of women with biopsy-proven, high-grade VIN
    • Site: Single large referral center
  • Relevant demographic characteristics were recorded
  • All women were counseled on options of
    • Excision
    • laser ablation
    • 5-flouroucil
  • Treatment was administered according to a standardized regimens
  • Recurrence was defined as a biopsy showing any VIN diagnosis after primary treatment
  • Primary objective
    • Treatment success and recurrence rates in patients treated with 5-fluourouracil for high-grade VIN
  • Secondary objective
    • Compare 5-fluorouracil treatment with excision and laser ablation

RESULTS:

  • 47 patients were treated with 5-flourouracil, 35 with excision, and 22 with laser ablation
  • Demographics were similar between groups
  • No recurrence was observed in
    • 74% treated with 5-flourouracil (95% CI 62–87%)
    • 57% treated with excision (95% CI 41–74%)
    • 41% treated with laser ablation: (95% CI 20–61%)
  • 13 patients treated with 5-fluorouracil for recurrence
    • 8 (62%) did not experience a second recurrence
  • 16% of patients treated with 5-fluorouracil reported a side effect
    • Irritation and dyspareunia were reported most commonly

CONCLUSION:

  • 5-fluorouracil has a 74% success rate as the initial treatment of high-grade vaginal dysplasia
  • 5-fluorouracil was effective even in the face of recurrence following first line treatment (including 5-fluorouracil)
  • Researchers acknowledge that the study was retrospective in nature, but the data supports 5-fluorouracil as a viable option in the treatment of high-grade VIN

Learn More – Primary Sources:

Topical 5-Fluorouracil for Women With High-Grade Vaginal Intraepithelial Neoplasia

 

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Vulvar Intraepithelial Neoplasia (VIN): Diagnosis and Treatment 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site